Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 7/20 | 0.36 |
| ▸ | F2 | P00734 | 6/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12606094 | 1.00 | BIRC2 (0.36) | BIRC2F2OPRM1PRSS1PLAT | |
| SCHEMBL12605993 | 0.94 | CTSB (0.36) | BIRC2F2PRSS1PLATNPSR1 | |
| SCHEMBL16329139 | 0.94 | CTSB (0.36) | BIRC2F2PRSS1PLATNPSR1 | |
| SCHEMBL12606105 | 0.92 | NPSR1 (0.39) | BIRC2F2PRSS1PLATNPSR1 | |
| SCHEMBL12606095 | 0.91 | NPSR1 (0.40) | BIRC2F2PRSS1PLATNPSR1 | |
| SCHEMBL12606093 | 0.89 | CAPN1 (0.39) | BIRC2F2XIAPBIRC3 | |
| SCHEMBL12606015 | 0.88 | NPSR1 (0.36) | BIRC2F2PRSS1PLATNPSR1 | |
| SCHEMBL12605988 | 0.88 | RAB9A (0.34) | BIRC2F2PRSS1PLATNPSR1 | |
| SCHEMBL12606103 | 0.87 | TSHR (0.39) | BIRC2ALDH1A1 | |
| SCHEMBL12605920 | 0.86 | F2 (0.39) | F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | BIRC2 564/4885F2 569/4885OPRM1 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.